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1. Introduction
Metalloproteinases (MMPs) were first described by Gross more than fifty years ago. They are
a family of zinc-dependent endopeptidases. They comprise a group of 25 enzymes. MMPs
were first described as proteases degrading extracellular matrix (ECM) proteins such as
collagens, elastin, proteoglycans and laminins, hence they were named matrix metalloprotei‐
nases. MMPs were divided according to their substrate specificity into collagenases, gelati‐
nases, stromolysins and matrilysins. This classification was later replaced by numbering the
enzymes according to the chronology of their identification.
Four metalloproteinases (MMP-14, MMP-15, MMP-16 and MMP-24) have a transmembrane
and cytosolic domains. They constitute a subgroup of membrane-type metalloproteinases
(MT-MMPs). Recently an intracellular, nuclear localization and functions of metalloprotei‐
nases have been discovered [1-4].
2. Physiological role of metalloproteinases
MMP-1 (collagenase 1) hydrolyzes collagen types I, II, III, VII, VIII, X and XI, as well as gelatin,
fibronectin, vitronectin, laminin, tenascin, aggrecan, links protein, myelin basic protein and
versican. MMP-2 (gellatinase) degrades collagen types I, II, III, IV, V, VII, X and XI, gelatin,
elastin, fibronectin, vitronectin, laminin, entactin, tenascin, SPARC and aggrecan, links
protein, galectin-3, versican, decanin and myelin basic protein. One of the most important
differences between these two metalloproteinases is the possibility of the hydrolysis of elastin
and collagen type IV by MMP-2, but not by MMP-1. Researchers have also focused their interest
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on MMP-9 which can degrade collagen types IV, V, VII, X and XIV, fibronectin, laminin,
nidogen, proteoglycan link protein and versican.
For a long time metalloproteinases have been viewed solely as enzymes of matrix proteins
breakdown. Results of researches performed in recent years indicate that there is a group of
non-matrix proteins which can be substrates for various MMPs. Metalloproteinases are
involved in the activation of latent forms of effective proteins. For example, MMP-2, MMP-3
and MMP-9 can activate interleukin 1β (IL-1β). They can also act on active cytokines, IL-1β
undergoes subsequent degradation catalyzed by MMP-3. Metalloproteinases can alter cell
surface proteins such as receptors and act on microbial peptides.
Metalloproteinases are not indiscriminately released by cells. They are secreted to or anchored
to cell membrane. MT-MMPs have a specific transmembrane domain placing them in a certain
position. Other metalloproteinases can be bound by specific cell-MMP interactions. This
phenomenon allows an exact localization of their proteolytic activity [1-3].
3. Activation of metalloproteinases
Metalloproteinases are encoded as inactive proenzymes, zymogens. They undergo proteolytic
activation. This process can take place either intracellulary or extracellulary. One third of
MMPs are activated by intracellular serine protease, furin. This process takes place in trans-
Golgi network. A number of MMPs has a cleavage site for other metalloproteinases. MMP-3
activates proMMP-1 and pro-MMP-7. Some metalloproteinases have been described to be
activated by kallikrein or plasmin.
In vivo studies indicate that reactive oxygen species (ROS) generated by neutrophils can both
activate and subsequently inactivate MMPs. Hypochlorus acid (HClO) generated by neutro‐
phil myeloperoxidase and hydroxyl radicals can activate proMMP-1, proMMP-7 and
proMMP-9, whereas peroxynitrate can activate proenzymes of MMP-1, MMP-2 and MMP-9.
This process enables a control of burst of proteolytic activity within an inflammatory setting.
Like some other proteases, activity of MMPs is controlled also by two other mechanisms,
regulation of gene expression and specific inhibitors. MMP-2 is constitutively expressed and
regulation of its activity occurs by either activation or inhibition. Expression of a number of
metalloproteinases is up-regulated during various pathological conditions. Among them
inflammation is the most studied setting. MMPs are inhibited by α-2 macroglobulin and tissue
inhibitors of metalloproteinases (TIMPs). There are four TIMPs. Their secretion is also
regulated and represents another point in a network of control of the activity of metallopro‐
teinases. TIMP-3 is primarily bond to ECM and allows a regulation of MMPs’ activity in the
very site of their action. The network of the control of the activity of metalloproteinases is
complex and very precise. Sometimes TIMP interacts with proMMP and inactivate other MMP,
e.g. a complex of TIMP-1 and proMMP-9 inactivates MMP-3.
Protection from MMP degradation represents the next step in this sophisticated network of
diverse interactions. Neutrophil gelatinase-associated lipocalin (NGAL) bounds to MMP-9
protecting this metalloproteinase from its degradation [1-3].
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4. Metalloproteinases in central nervous system
Metalloproteinases in central nervous system can be produced by cells constituting it, by cells
of blood vessels’ wall or by blood cells. The production of MMPs in central nervous system
under normal conditions is low, however it can be augmented in several neoplastic and non-
neoplastic conditions. The expression of MMP-14 (MT1-MMP) in microglia is very low under
physiological conditions. It can be increased in neurodegenerative and neuroinflammatory
pathologies, e.g. Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS)
or even in a stroke. Astrocytes were reported to secrete MMP-2 and MMP-9 [5,6].
For a long time MMPs were thought to be enzymes acting exclusively in extracellular compart‐
ment.  Studies  carried in  last  few years  have revealed nontraditional  roles  for  MMPs in
extracellular space as well as in the cytosol and nucleus. MMP-2 and MMP-9 which were largely
studied in central nervous system have been shown to present an increased activity in cortex
neuronal nuclei after focal cerebral ischemia. These two MMPs, MMP-2 and MMP-9, are also
termed gelatinase A and gelatinase B. The increased gelanolytic activity in nucleus occurs to be
linked with MMP-dependent cell death triggering neuroinflammatory reactions. MMP-13,
named also collagenase-3, was found to be activated mostly in neurons and oligodendro‐
cytes. Its function in cell nucleus may be linked to the apoptosis cascade following ischemic
stimulus. MMPs localized in cell nucleus can have a different set of target proteins than MMPs
acting  in  extracellular  space.  Poly-ADP-ribose  polymerase-1  (PARP-1)  and  X-ray  cross-
complementary factor-1 (XRCC-1) can be the substrates for MMP-dependent cleavage [4].
5. Metalloproteinases in brain tumors
Gliomas are the most common malignant tumors in the brain, and the overall prognosis for
patients suffering from this neoplasm is poor. Glioblastoma multiforme (GBM) is the most
aggressive type of glioma. Molecular mechanisms of invasiveness of this neoplasm have been
most widely studied. Many factors are involved in the migration and invasiveness of GBM.
MMPs have gained a large interest of researchers. The role of MMPs is significant in the
degradation of ECM, thereby facilitating tumor cell invasion into surrounding stroma.
Neoplastic cell invades in three steps. The first one is the attachment of tumor cell to the
basement membrane through binding of neoplastic cell receptors to the basement membrane
receptors. The next one is the secretion of hydrolytic enzymes, MMPs, which locally degrade
ECM by extracellular proteolysis. The third step comprises the movement of the tumor cell to
the free space obtained by degradation of ECM. MMP-13 is involved in the initiation of
progression of invasion due to its proteolytic activity. Expression of MMP-13 is higher in
glioma than in the surrounding normal brain tissue. High expression of this MMP is more
often detected in advanced grades of glioma. Some researchers suggest that MMP-13 can be
used as a biomarker of GBM progression. A study of Hsieh et al. revealed that GBM cells
express higher amount of endothelin-1 receptors ETA and ETB. The stimulation of one of the
most invasive glioma cell lines in vivo, U251, with endothelin resulted in an increased expres‐
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sion of MMP-13, MMP-9 and increased cell migration. The addition of MMP-13 and MMP-9
inhibitors attenuated this increased cell migration [7-9].
Other scientists have shown that GBM cells can present an increased expression of other
metalloproteinases: MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 and MMP-14. Some researchers
tried to reveal the molecular markers of invasiveness in gliomas. In the results of their studies
various MMPs can be found. Bakalova et al. found that patients in terminal stages of brain
tumors had elevated plasma levels of MMP-2 and MMP-9. Mariani et al. measured levels of
MMP-2 and MMP-9 in cerebrospinal fluid (CSF) of dogs with intracranial tumors. Latent, but
not active form of MMP-2 was found in all samples. MMP-9 was found in CSF of a minority
of studied animals. Xu et al. analyzed brain samples obtained from patients undergoing
surgery for GBM and non-malignant condition, epilepsy. Overexpression of both MMP-1 and
vascular endothelial growth factor-1 (VEGF-1) was an independent poor prognostic factor in
gliomas. Wang and co-workers analyzed frozen glioma samples and found out an increased
expression of stromal periostin (POSTN) gene. This protein took part in both cell invasion and
migration. In glioma cells POSTN signaling led to increased MMP-9 expression. The expres‐
sion of POSTN correlated with both grade and progression of glioma being a poor prognostic
factor [10-13].
MT1-MMP (MMP-14) activates directly proMMP-2 and indirectly MMP-2 and MMP-9.
Expression of MMP-14 was shown to correlate with invasiveness of glioma and to increase
with glioma grade. MMP-14 expression was also shown to correlate with brain tumor pro‐
gression. This metalloproteinase, MMP-14, has been proposed as a biomarker to determine the
type and grade of specific tumor. MMP-14 has a very interesting set of digested proteins. Apart
from ECM proteins it can hydrolyze the most potent central nervous myelin inhibitory
proteins, including BN-220. MMP-14 can also digest some proteins having adhesion functions.
MMP-14 can also be involved in some intracellular processes. It can be trafficked along the
tubulin cytoskeleton and be involved in intracellular recycling pathway. MMP-14 expression
abnormalities were linked to mitotic spindle aberrations and chromosome instability leading
to malignant transformation of neoplastic cells. MMP-14 may also be involved in regulation
of VEGF-A expression. VEGF-A induces angiogenesis and inhibits apoptosis. MMP-14 seems
to promote malignant glioma transformation, invasion and metastasis through intracellular
signaling pathways [14].
6. Metalloproteinases and intracellular signaling pathways
Increased expression of various MMPs observed in brain tumors is a result of multiple
intracellular events which may be termed as dysregulated pathways. These intracellular
molecular mechanisms leading to increased invasion of neoplasmatic cells have focused
scientists’ interest. Understanding these complex mechanisms may be a key to design a
molecular targeted therapy for patients with brain tumors. Signaling pathways leading to
increased expression of MMPs are of special interest.
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Tsai et al. observed that inhibition of focal adhesion kinase (FAK) phosporylation by osthole
reduced MMP-13 expression in human glioma cells. This inhibition led to a reduction of cells
migration even in a subgroup of glioma cells selected for high migratory ability. Lee et al.
observed GMB U251 cell line presented increased FAK activation which led to an augmented
expression of MMP-2. This study also revealed that examined GBM cells had an increased Bcl-
w (B-cell lymphoma-w) expression. This protein is a prosurvival member of Bcl-2 family. The
augmented expression of this protein is associated with infiltration properties and aggres‐
siveness of various cancers. Bcl-w promotes the mesenchymal traits of glioblastoma cells by
inducing vimentin expression of transcription factors, β-catenin, Twist1 and Snail. The
increased expression of MMP-2 is accompanied by and results from the FAK activation, i.e.
phosphorylation, via the PI3K-p-Akt-p-GSK3β-β-catenin pathway. The role of Bcl-w in
promoting invasiveness of GBM by increasing MMP-2 activation was also confirmed in
another study of this researchers team which proposed Bcl-w induced activation of β-catenin,
also termed specificity protein-1 (Sp1), as a putative marker for aggressiveness of GBM.
Nuclear factor of activated T cell (NFAT) family has been identified as a group of regulators
of oncogenic transformation in several human malignancies. NFAT1 (NFATc2) is the prevalent
family member expressed in peripheral T lymphocytes and many other cells outside the
immune system. It is associated with tumor cell survival, apoptosis, migration and invasion.
Clustering analysis of microarray data revealed that in glioma cells the expression of invasion
related genes, cyclooxygenase-2 (COX-2), MMP-7 and MMP-9, was correlated with the
expression of NFAT1. In vitro analysis confirmed the role of NFAT1, as in a specific NFAT1
knock down in U87 glioma cell line led to a marked reduction of COX-2, MMP-7 and MMP-9
expression [7,15-17].
MMP-2 has been discovered to posses intracellular activity and play some role in cell nucleus.
A study by Kesanakurti et al. put new light on a role of MMP-2 in molecular mechanisms
engaged in aggressiveness of glioma cells. p21 activated kinase 4 (PAK4) is one of down stream
effectors of small GTPases Rac1 and Cdc42 which have diverse cellular functions by regulating
cytoskeletal reorganization, cell survival and angiogenesis. Abberant PAK4 expression was
found to be associated with enhanced tumor progression in various carcinomas. MMP-2
directly interacts with PAK-4 and augments the activation of αvβ3-mediated phospho-
epidermal growth factor receptor (phospho-EGFR) in GBM. MMP-2 is supposed to bind to
PAK4 and the complex PAK4/MMP-2 is supposed to regulate integrin mediated pathways in
gliomas. Earlier study of Kesanakurti study group revealed that MMP-2 knock down glioma
cells entered on apoptosis pathway [18-20].
Understanding the molecular pathways enhancing aggressiveness of glioma cells may lead
to  introducing  a  complex  therapy  focused  on  several  targets  which  may  give  a  better
effectiveness.
7. Metalloproteinases in other cells supporting tumor and metastasis
development
In last few years scientists have paid more attention to interactions between glioma cells and
microglia as well as on inreactions between metastatic cancer cells and astrocytes. Ellert-
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Miklaszewska et al. observed that glioma attracted microglia and polarized them into tumor-
supporting cells that participated in matrix-remodeling, invasion, angiogenesis and
suppression of adaptative immunity. In her experiment rat microglial cultures exposed to
glioma conditioned medium polarized into pro-inflammatory or alternatively activated cells.
Glioma derived factors increased cell motility, phagocytosis and sustained proliferation.
Glioma induced activation of microglia was associated with induction of expression of several
genes. One of them was MT1-MMP. Vinnakota et al. also observed that microglia promoted
glioma through upregulation of MT1-MMP. This conversion of microglia into glioma suppor‐
tive phenotype was dependent on activation of Toll-like receptor 2 (TLR 2) along with TLR 1
and or TLR 6 signaling [21, 22].
Brain metastasis is a defining component of tumor pathophysiology and underlying mecha‐
nisms urgently need deeper elucidation. The relationship between metastatic cells and
astrocytes is crucial for tumor cell sustenance in brain. Some researchers postulate that tumor
cell metastasis to the brain are influenced by astrocyte secretome and astrocytes play a direct
role in tumor metastasis. Wang et al. revealed that astrocyte conditioned tumor cells displayed
highly invasive and metastatic behavior both in vitro and in vivo as well. MMP-2 and MMP-9
were two factors in the astrocyte secretome that were responsible for that response. Blocking
these MMPs proteins partially prevented the invasion and metastasis of tumor cells both in
vitro and in vivo as well. A very important question arises. What are the mechanisms by which
MMPs secreted by astrocytes trigger invasion of tumor cells? MMP-2 and MMP-9 may increase
the permeability of blood-brain barrier and allow the transfer of metastatic cells reaching brain
via blood stream. The alternative hypothesis is that latent MMPs substrates on tumor cells or
cells of tumor microenvironment may be activated upon cleavage by astrocyte secreted MMP-2
and MMP-9 leading to an invasive phenotype. The precise elucidation of these interactions is
urgent as astrocytes may be a novel target for therapy aimed at prevention of brain metastases
in patients with various cancers [21-23].
8. Blocking MMPs expression and/or activity
Scientists have widely studied the possibilities of attenuating MMPs expression and activity
in order to reduce the invasiveness of gliomas. They efforts have combined various directions.
Atorvastatin is a well known statin, an inhibitor of β-hydroxy-β-methylglutaryl-CoA reduc‐
tase. By inhibiting the key enzyme in a mevalonate synthesis pathway atorvastatin has
pleiotropic effects. The main mode of action of this drug is the inhibition of de novo cholesterol
synthesis. However, this drug has some other advantages resulting in its pleiotropic antia‐
therogenic properties due to the inhibition of synthesis of other biologically important
mevalonate pathway derivates: dolichol, ubichinon, farnesyl and geranyl residues. This
inhibition leads to disturbances in some signaling pathways. The possible anticancer proper‐
ties of statins have been postulated since a long time.
Yongjun and co-workers have observed that atorvastatin reduced pro-tumorigenic effects of
microglia on glioma migration and invasion by reducing microglial expression of MT1-MMP
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor120
(MMP-14). Mohebbi et al. observed that atorvastatin 40 mg administered twice daily seven
from days before till three weeks after the neurosurgical procedure led to better outcome after
the neurosurgical treatment of brain tumors and raised significantly Karnofsky score. The
biochemical analysis showed that two weeks after the surgical treatment patients on atorvas‐
tatin therapy had significantly reduced plasma level of MMP-9 compared to patients receiving
placebo [24,25].
Locatelli et al. evaluated a composition of polymeric nanoparticles containing a composition
of two cytotoxic agents, drug alisertib and nanosilver conjugated with chlorotoxin, a peptide
binding specifically to MMP-2. Their experimental in vitro and in vivo studies showed the tumor
reduction [26].
Researchers are trying to investigate drugs aimed at inhibiting MT1-MMP (MMP-14). DX-2400,
a fully human antibody was shown to reduce MMP-14 activity, retard tumor progression,
metastasis, migration and invasion. Two natural isoflavonoid phytoestrogens, genistein and
biochain A, were shown to reduce MMP-14 activity in a dose dependent manner in U87MG
cell line. The green tea polyphenol, (Q)-epigallocatechin gallate (EGCg), has been found to
inhibit MMP-14 mediated cell migration. This compound also disrupted proMMP-2 activation
via downregulation of MMP-14 gene expression. Marimastat, an orally administered MMP
inhibitor, was tested in two clinical trials in GBM patients after neurosurgery or irradiation.
Marimastat alone did not improve survival, but in conjunction with cytotoxic chemotherapy
gave promising results [27-30].
The next point of scientists interest are microRNAs (miRNAs). These small, non-coding RNA
molecules containing 18-25 nucleotides in length can inhibit gene expression by binding to the
3’ untranslated region of their target genes and suppress translation. Several studies have
shown that various miRNAs can inhibit expression of MMP-14, MMP-2 and inhibit tumor cell
adhesion, migration, invasion and angiogenesis [31-35].
Lei et al. proposed a new strategy combining a cytotoxic drug paclitaxel and RNA interference
suppressing MMP-2 expression. This conception was aimed at blocking tumor growth and
proliferation by Paclitaxel and blocking tumor angiogenesis and invasion by inhibiting MMP-2
expression [36].
9. Conclusions
In last few years MMPs have been shown to exert new biochemical properties. Their extrac‐
ellular mode of action as well as intracellular, intranuclear activities were shown to be involved
in invasiveness of brain tumors, especially gliomas. Inhibiting their expression may be a new
therapeutical approach. So far some drugs being MMPs inhibitors have some serious adverse
effects. Inhibiting MMPs expression and activity seems to be rather a supplement to chemo‐
therapy, radiotherapy or neurosurgical procedures than a new single method of treatment of
brain tumors.
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